# Department of Defense PTSD Adaptive Platform Trial - Master Protocol

> **NCT05422612** · PHASE2 · RECRUITING · sponsor: **Global Coalition for Adaptive Research** · enrollment: 800 (estimated)

## Conditions studied

- Post Traumatic Stress Disorder

## Interventions

- **DRUG:** Intervention A Fluoxetine Hydrochloride (HCl)
- **DRUG:** Intervention A Placebo
- **DRUG:** Intervention B Vilazodone Hydrochloride (HCl)
- **DRUG:** Intervention B Placebo
- **DRUG:** Intervention C Daridorexant
- **DRUG:** Intervention C Placebo
- **DRUG:** Intervention D SLS-002
- **DRUG:** Intervention D Placebo

## Key facts

- **NCT ID:** NCT05422612
- **Lead sponsor:** Global Coalition for Adaptive Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-02
- **Primary completion:** 2026-03
- **Final completion:** 2026-09
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2025-09-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05422612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05422612, "Department of Defense PTSD Adaptive Platform Trial - Master Protocol". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05422612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*